Clinical Trial Update: Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and immunogenicity of a 20-valent pneumococcal vaccine in adults 65+ with prior vaccination; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 20-valent pneumococcal vaccine

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-02-21